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Abstract 
Bioanalytical method based on a variety of physico-chemical and biological techniques such as chromatography, 
immunoassay and mass spectrometry, must be validated prior to and during use to give confidence in the results generated. 
It is the process used to establish that a quantitative analytical method is suitable for biomedical applications. Bioanalytical 
method validation includes all of the procedures that demonstrate that a particular method used for quantitative 
measurement of analytes in a given biological matrix, such as blood, plasma, serum, or urine is reliable and reproducible for 
the intended use. The present manuscript focuses on the consistent evaluation of the key bioanalytical validation parameters 
is discussed: accuracy, precision, sensitivity, selectivity, standard curve, limits of quantification, range, recovery and 
stability. These validation parameters are described, together with an example of validation methodology applied in the 
case of chromatographic methods used in bioanalysis, taking in account to the recent Food and Drug Administration (FDA) 
guidelines and EMA guide 
Keywords: Bioanalytical method, Method development, chromatography. 
 
1. Introduction 
The development of sound bioanalytical method(s) 
is of paramount importance during the process of drug 
discovery and development, culminating in a marketing 
approval. The objective of this paper is to review the 
sample preparation of drug in biological matrix and to 
provide practical approaches for determining selectivity, 
specificity, limit of detection, lower limit of quantization, 
linearity, range, accuracy, precision, recovery, stability, 
ruggedness, and robustness of liquid chromatographic 
methods to support pharmacokinetic (PK), toxicokinetic, 
bioavailability, and bioequivalence studies. Bioanalysis, 
employed for the quantitative determination of drugs and 
their metabolites in biological fluids, plays a significant role 
in the evaluation and interpretation of bioequivalence, PK, 
and toxicokinetic studies. Selective and sensitive analytical 
methods for quantitative evaluation of drugs and their 
metabolites are critical for the successful conduct of pre-
clinical and/or biopharmaceutics and clinical pharmacology 
studies. The process by which a specific bioanalytical 
method is developed, validated, and used in routine sample 
analysis can be divided into three stapes as below [1,2]. 
1) Reference standard preparation, 
2) Bioanalytical method development and establishment of 
assay procedure and 
3) Application of validated bioanalytical method to routine 
drug analysis and acceptance criteria for the analytical 
run and/or batch. 
 
2. Selectivity  
The analytical method should be able to 
differentiate the analyte(s) of interest and IS from 
endogenous components in the matrix or other components 
in the sample. Selectivity should be proved using at least 6 
individual sources of the appropriate blank matrix, which 
are individually analysed and evaluated for interference. 
Use of fewer sources is acceptable in case of rare matrices. 
Normally, absence of interfering components is accepted 
where the response is less than 20% of the lower limit of 
quantification for the analyte and 5% for the internal 
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standard. It may also be necessary to investigate the extent 
of any interference caused by metabolites of the drug(s), 
interference from degradation products formed during 
sample preparation, and interference from possible co-
administered medications. Co-medications normally used in 
the subject population studied which may potentially 
interfere should be taken into account at the stage of 
method validation, or on a study specific and compound 
specific base. The extent of back-conversion should be 
established and the impact on the study results discussed. It 
is acknowledged that this evaluation will not be possible 
early during drug development of a new chemical entity 
when the metabolism is not yet evaluated. However, it is 
expected that this issue is taken into account and a partial 
validation is performed if relevant as further knowledge 
regarding metabolism of the active substance is gained 
during drug development. It is recognized that in some 
cases it is very difficult to obtain the metabolites of interest. 
Alternatively, back-conversion of a metabolite can be 
checked by applying incurred sample reanalysis. However, 
in this case potential back conversion during sample 
processing cannot be ruled out [3,4] 
 
3. Carry-over (AICO) 
Carry-over should be addressed and minimised 
during method development. During validation carryover 
should be assessed by injecting blank samples after a high 
concentration sample or calibration standard at the upper 
limit of quantification. Carry over in the blank sample 
following the high concentration standard should not be 
greater than 20% of the lower limit of quantification 
(LLOQ; see below) and 5% for the internal standard. If it 
appears that carry-over is unavoidable, study samples 
should not be randomized. Specific measures should be 
considered, tested during the validation and applied during 
the analysis of the study samples, so that it does not affect 
accuracy and precision. This could include the injection of 
blank samples after samples with an expected high 
concentration, before the analysis of the next study 
sample[5]. 
 
4. Lower limit of quantification (LLOQ) 
 The lower limit of quantification (LLOQ) is the 
lowest concentration of analyte in a sample which can be 
quantified reliably, with an acceptable accuracy and 
precision. The LLOQ is considered being the lowest 
calibration standard (see Accuracy and Precision). In 
addition, the analyte signal of the LLOQ sample should be 
at least 5 times the signal of a blank sample. The LLOQ 
should be adapted to expected concentrations and to the aim 
of the study. As an example, for bioequivalence studies the 
LLOQ should be not higher than 5% of the Cmax, while such 
a low LLOQ may be not necessary for exploratory 
pharmacokinetic studies. 
 
5. Calibration curve  
The response of the instrument with regard to the 
concentration of analyte should be known, and should be 
evaluated over a specified concentration range. The 
calibration standards should be prepared in the same matrix 
as the matrix of the intended study samples by spiking the 
blank matrix with known concentrations of the analyte. 
There should be one calibration curve for each analyte 
studied in the method validation and for each analytical run. 
Ideally, before carrying out the validation of the analytical 
method it should be known what concentration range is 
expected. This range should be covered by the calibration 
curve range, defined by the LLOQ being the lowest 
calibration standard and the upper limit of quantification 
(ULOQ), being the highest calibration standard. The range 
should be established to allow adequate description of the 
pharmacokinetics of the analyte of interest. A minimum of 
six calibration concentration levels should be used, in 
addition to the blank sample (processed matrix sample 
without analyte and without IS) and a zero sample 
(processed matrix with IS).  
Each calibration standard can be analysed in 
replicate. A relationship which can simply and adequately 
describe the response of the instrument with regard to the 
concentration of analyte should be applied. The blank and 
zero samples should not be taken into consideration to 
calculate the calibration curve parameters. The calibration 
curve parameters should be reported (slope and intercept in 
case of linear fit). In addition, the back calculated 
concentrations of the calibration standards should be 
presented together with the calculated mean accuracy 
values (see definition of Accuracy below). All the available 
(or acceptable) curves obtained during validation, with a 
minimum of 3 should be reported. The back calculated 
concentrations of the calibration standards should be within 
±15% of the nominal value, except for the LLOQ for which 
it should be within ±20%. At least 75% of the calibration 
standards, with a minimum of six calibration standard 
levels, must fulfill this criterion [6,7]. 
 
6. Accuracy 
The accuracy of an analytical method describes the 
closeness of the determined value obtained by the method 
to the nominal concentration of the analyte (expressed in 
percentage). Accuracy should be assessed on samples 
spiked with known amounts of the analyte, the quality 
control samples (QC samples). The QC samples should be 
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spiked independently from the calibration standards, using 
separately prepared stock solutions, unless the nominal 
concentration(s) The QC samples are analysed against the 
calibration curve, and the obtained concentrations are 
compared with the nominal value. The accuracy should be 
reported as percent of the nominal value. 
A) Within-run accuracy Within-run accuracy should be 
determined by analysing in a single run a minimum of 5 
samples per level at a minimum of 4 concentration levels 
which are covering the calibration curve range: the LLOQ, 
within three times the LLOQ (low QC), around 30 - 50% of 
the calibration curve range (medium QC), and at least at 
75% of the upper calibration curve range (high QC). The 
mean concentration should be within 15% of the nominal 
values for the QC samples, except for the LLOQ which 
should be within 20% of the nominal value. 
B) Between–run accuracy in the between-run accuracy, 
LLOQ, low, medium and high QC samples from at least 
three runs analysed on at least two different days should be 
evaluated. The mean concentration should be within 15% of 
the nominal values for the QC samples, except for the 
LLOQ which should be within 20% of the nominal 
value.[9,10] 
 
7. Precision 
 The precision of the analytical method describes 
the closeness of repeated individual measures of analyte. 
Precision is expressed as the coefficient of variation (CV). 
Precision should be demonstrated for the LLOQ, low, 
medium and high QC samples 
A) Within-run precision For the validation of the within-
run precision, there should be a minimum of five samples 
per concentration level at LLOQ, low, medium and high 
QC samples in a single run. The within-run CV value 
should not exceed 15% for the QC samples, except for the 
LLOQ which should not exceed 20%.  
B) Between –run precision For the validation of the 
between-run precision, LLOQ, low, medium and high QC 
samples from at least three runs analysed on at least two 
different days should be evaluated. The between-run CV 
value should not exceed 15% for the QC samples, except 
for the LLOQ which should not exceed 20% 
 
8. Dilution integrity 
Dilution of samples should not affect the accuracy 
and precision. If applicable, dilution integrity should be 
demonstrated by spiking the matrix with an analyte 
concentration above the ULOQ and diluting this sample 
with blank matrix (at least five determinations per dilution 
factor). Accuracy and precision should be within the set 
criteria, i.e. within ±15%. Dilution integrity should cover 
the dilution applied to the study samples.[11] 
9. Matrix effect  
Matrix effects should be investigated when using 
mass spectrometric methods, using at least 6 lots of blank 
matrix from individual donors. Pooled matrix should not be 
used. For each analyte and the IS, the matrix factor (MF) 
should be calculated for each lot of matrix, by calculating 
the ratio of the peak area in the presence of matrix 
(measured by analyzing blank matrix spiked after extraction 
with analyte), to the peak area in absence of matrix (pure 
solution of the analyte). The IS normalized MF should also 
be calculated by dividing the MF of the analyte by the MF 
of the IS. The CV of the IS-normalized MF calculated from 
the 6 lots of matrix should not be greater than 15 %. This 
determination should be done at a low and at a high level of 
concentration (maximum of 3 times the LLOQ and close to 
the ULOQ). The overall CV calculated for the 
concentration should not be greater than 15 %.[12,13] 
 
10. Stability study 
The following stability tests should be evaluated:  
 Stability of the stock solution and working solutions of 
the analyte and internal standard, 
 Freeze and thaw stability of the analyte in the matrix 
from freezer storage conditions to room      
temperature or sample processing temperature 
 Short term stability of the analyte in matrix at room 
temperature or sample processing temperature  
 Long term stability of the analyte in matrix stored in the 
freezer 
 The calibration curve and coefficient of variation is 
shown in diagram of with their regration it should not 
more then 0.999 to get perfect calibration curve.(14,15) 
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